Takeda, Amitiza buyers to litigate damages calculation after US antitrust trial
Takeda Pharmaceuticals and a class of Amitiza buyers are set to litigate possible adjustments to damages calculations in the wake of a US jury finding Takeda unlawfully paid to delay generic...To view the full article, register now.
Already a subscriber? Click here to view full article